Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine
Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in
patients with NSCLC. Each agent and sequence has well demonstrated antitumor activity
respectively in patients with locally advanced or metastatic NSCLC. Therefore, it is
reasonable to investigate the most optimal schedule for this combination, and which
combination is associated with the most anti-tumor activity in the phase II arena.